Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 11, 2014, Pages 6471-6476

  Flanagan, S ^a   Minassian, S L ^b   Morris, D ^c   Ponnuraj, R ^c   Marbury, T C ^d   Alcorn, H W ^e   Fang, E ^a   Prokocimer, P ^a  

^a Cubist Pharmaceuticals   (United States)

^b Minassian Biostatistics Inc   (United States)

^c 206 Carnegie Center   (United States)

^d ORLANDO CLINICAL RESEARCH CENTER   (United States)

^e DAVITA CLINICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TEDIZOLID; ANTIINFECTIVE AGENT; ORGANOPHOSPHATE; OXAZOLE DERIVATIVE; OXAZOLIDINONE DERIVATIVE; PRODRUG; TETRAZOLE DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; FLATULENCE; FLUSHING; HAIR GROWTH; HEADACHE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER FAILURE; LIVER FUNCTION; MAXIMUM PLASMA CONCENTRATION; NAUSEA AND VOMITING; SIDE EFFECT; ADOLESCENT; BACTERIAL INFECTIONS; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CROSSOVER PROCEDURE; FEMALE; KIDNEY; LIVER; LIVER DISEASE; MALE; MICROBIOLOGY; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BACTERIAL INFECTIONS; CROSS-OVER STUDIES; FEMALE; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; LIVER; LIVER DISEASES; MALE; MIDDLE AGED; ORGANOPHOSPHATES; OXAZOLES; OXAZOLIDINONES; PRODRUGS; RENAL DIALYSIS; TETRAZOLES; YOUNG ADULT;

EID: 84908297834     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03431-14     Document Type: Article

References (40)

1. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48:1-12. http://dx.doi.org/10.1086/595011.
2. Gould IM, David MZ, Esposito S, Garau J, Lina G, Mazzei T, Peters G. 2012. New insights into methicillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance. Int. J. Antimicrob. Agents 39:96-104. http://dx.doi.org/10.1016/j.ijantimicag.2011.09.028.
3. Moran GJ, Abrahamian FM, Lovecchio F, Talan DA. 2013. Acute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelines. J. Emerg. Med. 44:e397-e412. http://dx.doi.org/10.1016/j.jemermed.2012.11.050.
4. Kanafani ZA, Corey GR. 2012. Tedizolid (TR-701): a new oxazolidinone with enhanced potency. Expert Opin. Invest. Drugs 21:515-522. http://dx.doi.org/10.1517/13543784.2012.660250.
5. Urbina O, Ferrández O, Espona M, Salas E, Ferrández I, Grau S. 2013. Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections. Drug Des. Dev. Ther. 7:243-265. http://dx.doi.org/10.2147/DDDT.S30728.
6. Prokocimer P, Bien P, Surber J, Mehra P, DeAnda C, Bulitta JB, Corey GR. 2011. Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrob. Agents Chemother. 55:583-592. http://dx.doi.org/10.1128/AAC.00076-10.
7. Prokocimer P, De Anda C, Fang E, Mehra P, Das A. 2013. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA 309:559-569. http://dx.doi.org/10.1001/jama.2013.241.
8. Moran GJ, Fang E, Corey GR, Das AF, De Anda C, Prokocimer P. 2014. Once-daily tedizolid for 6 days versus twice-daily linezolid for 10 days in acute bacterial skin and skin structure infections: results from a randomised controlled trial using an intravenous-to-oral switch strategy (ESTABLISH-2 study). Lancet Infect. Dis. 14:696-705. http://dx.doi.org/10.1016/S1473-3099(14)70737-6.
9. Flanagan SD, Bien PA, Muñoz KA, Minassian SL, Prokocimer PG. 2014. Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug. Pharmacotherapy 34:240-250. http://dx.doi.org/10.1002/phar.1337.
10. Bergman SJ, Speil C, Short M, Koirala J. 2007. Pharmacokinetic and pharmacodynamic aspects of antibiotic use in high-risk populations. Infect. Dis. Clin. North Am. 21:821-846. http://dx.doi.org/10.1016/j.idc.2007.07.004.
11. Heintz BH, Matzke GR, Dager WE. 2009. Antimicrobial dosing concepts and recommendations for critically ill adult subjects receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 29:562-577. http://dx.doi.org/10.1592/phco.29.5.562.
12. Naqvi SB, Collins AJ. 2006. Infectious complications in chronic kidney disease. Adv. Chronic Kidney Dis. 13:199-204. http://dx.doi.org/10.1053/j.ackd.2006.04.004.
13. Canedo J, Ricciardi K, DaSilva G, Rosen L, Weiss EG, Wexner SD. 2013. Are postoperative complications more common following colon and rectal surgery in patients with chronic kidney disease? Colorectal Dis. 15:85-90. http://dx.doi.org/10.1111/j.1463-1318.2012.03099.x.
14. Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Jr, Craig WA, Billeter M, Dalovisio JR, Levine DP. 2009. Therapeutic monitoring of vancomycin in adults: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am. J. Health Syst. Pharm. 66:82-98. http://dx.doi.org/10.2146/ajhp080434.
15. Ikuta S, Tanimura K, Yasui C, Aihara T, Yoshie H, Iida H, Beppu N, Kurimoto A, Yanagi H, Mitsunobu M, Yamanaka N. 2011. Chronic liver disease increases the risk of linezolid-related thrombocytopenia in methicillin-resistant Staphylococcus aureus-infected patients after digestive surgery. J. Infect. Chemother. 17:388-391. http://dx.doi.org/10.1007/s10156-010-0188-8.
16. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. 2007. Prevalence of chronic kidney disease in the United States. JAMA 298:2038-2047. http://dx.doi.org/10.1001/jama.298.17.2038.
17. Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, Srishord M. 2011. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin. Gastroenterol. Hepatol. 9:524-530. http://dx.doi.org/10.1016/j.cgh.2011.03.020.
18. Matzke GR, Frye RF. 2008. Drug therapy individualization for subjects with renal insufficiency, p 833-844. In DiPiro J, Talbert RL, Yee G, Matzke G, Wells B, Posey LM (ed), Pharmacotherapy: a pathophysiologic approach, 7th ed. McGraw-Hill Medical, New York, NY.
19. Nolin TD. 2008. Altered nonrenal drug clearance in ESRD. Curr. Opin. Nephrol. Hypertens. 17:555-559. http://dx.doi.org/10.1097/MNH.0b013e3283136732.
20. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F. 2006. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann. Intern. Med. 145:247-254. http://dx.doi.org/10.7326/0003-4819-145-4-200608150-00004.
21. 14C]-TR-701 FA in healthy subjects, poster A2-033. 51st Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
22. US Food and Drug Administration, Center for Drug Evaluation and Research. March 2010. Guidance for industry. Pharmacokinetics in patients with impaired renal function - study design, data analysis, and impact on dosing and labeling. Draft guidance, revision 1. Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD. http://www.fda.gov/downloads/Drugs/./Guidances/UCM204959.pdf. Accessed 15 April 2014.
23. Vilay AM, Churchwell MD, Mueller BA. 2008. Clinical review: drug metabolism and nonrenal clearance in acute kidney injury. Crit. Care 12:235. http://dx.doi.org/10.1186/cc7093.
24. Sun H, Frassetto LA, Huang Y, Benet LZ. 2010. Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease. Clin. Pharmacol. Ther. 87:465-472. http://dx.doi.org/10.1038/clpt.2009.247.
25. Gonzalez F, Couthtrie M, Tukey RH. 2010. Drug metabolism, p 123-143. In Brunton L, Chambers B, Knollman B (ed), Goodman & Gilman's the pharmacologic basis of therapeutics, 12th ed. McGraw-Hill Education, New York, NY.
26. Takahashi Y, Takesue Y, Nakajima K, Ichiki K, Tsuchida T, Tatsumi S, Ishihara M, Ikeuchi H, Uchino M. 2011. Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy. J. Infect. Chemother. 17:382-387. http://dx.doi.org/10.1007/s10156-010-0182-1.
27. Sasaki T, Takane H, Ogawa K, Isagawa S, Hirota T, Higuchi S, Horii T, Otsubo K, Ieiri I. 2011. Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients. Antimicrob. Agents Chemother. 55:1867-1873. http://dx.doi.org/10.1128/AAC.01185-10.
28. Matsumoto K, Takeshita A, Ikawa K, Shigemi A, Yaji K, Shimodozono Y, Morikawa N, Takeda Y, Yamada K. 2010. Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction. Int. J. Antimicrob. Agents 36:179-181. http://dx.doi.org/10.1016/j.ijantimicag.2010.02.019.
29. Slatter JG, Stalker DJ, Feenstra KL, Welshman IR, Bruss JB, Sams JP, Johnson MG, Sanders PE, Hauer MJ, Fagerness PE, Stryd RP, Peng GW, Shobe EM. 2001. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects. Drug Metab. Dispos. 29:1136-1145.
30. Brier ME, Stalker DJ, Aronoff GR, Batts DH, Ryan KK, O'Grady M, Hopkins NK, Jungbluth GL. 2003. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob. Agents Chemother. 47:2775-2780. http://dx.doi.org/10.1128/AAC.47.9.2775-2780.2003.
31. Pfizer. 2013. Zyvox. US physician prescribing information. Pfizer, New York, NY.
32. Pea F, Viale P, Cojutti P, Del Pin B, Zamparini E, Furlanut M. 2012. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J. Antimicrob. Chemother. 67:2034-2042. http://dx.doi.org/10.1093/jac/dks153.
33. MacGowan AP. 2003. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and subjects with Gram-positive infections. J. Antimicrob. Chemother. 51(Suppl 2):ii17-ii25. http://dx.doi.org/10.1093/jac/dkg248
34. Dreisbach AW, Lertora JJ. 2008. The effect of chronic renal failure on drug metabolism and transport. Expert Opin. Drug Metab. Toxicol. 4:1065-1074. http://dx.doi.org/10.1517/17425255.4.8.1065.
35. Lodise TP, Drusano GL. 2014. Use of pharmacokinetic/pharmacodynamic systems analyses to inform dose selection of tedizolid phosphate. Clin. Infect. Dis. 58(Suppl 1):S28-S34. http://dx.doi.org/10.1093/cid/cit615.
36. Center for Biologics Evaluation and Research. 2003. Guidance for industry: pharmacokinetics in patients with impaired liver function: study design, data analysis, and impact on dosing and labeling. Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072123.pdf. Accessed 15 April 2014.
37. Reidenberg MM, Breckenridge A. 1998. Drugs and the liver. Clin. Pharmacol. Ther. 64: 353-354. http://dx.doi.org/10.1016/S0009-9236(98)90064-9.
38. Das D, Tulkens PM, Mehra P, Fang E, Prokocimer P. 2014. Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: safety summary. Clin. Infect. Dis. 58(Suppl 1):S51-S57. http://dx.doi.org/10.1093/cid/cit618.
39. Pea F, Scudeller L, Lugano M, Baccarani U, Pavan F, Tavio M, Furlanut M, Rocca GD, Bresadola F, Viale P. 2006. Hyperlactacidemia potentially due to linezolid overexposure in a liver transplant recipient. Clin. Infect. Dis. 42:434-435. http://dx.doi.org/10.1086/499533.
40. Su E, Crowley K, Carcillo JA, Michaels MG. 2011. Linezolid and lactic acidosis: a role for lactate monitoring with long-term linezolid use in children. Pediatr. Infect. Dis. J. 30:804-806. http://dx.doi.org/10.1097/INF.0b013e3182186035.